November 5 - Wednesday Afternoon

Opening Plenary Session: Congenital CMV Disease: Challenges and Solutions

1:00 -1:10

Welcome address

1:10 -1:15

Organizers' address - Lenore Pereira

1:15 -1:55

Keynote address - Gail Demmler: Public Health Action towards Awareness, Prevention, and Treatment

1:55 -3:15

Meet the families

3:15 -3:30

Break

Plenary I: Epidemiology

3:30 -3:50

Michael Cannon: Recent epidemiologic results that impact awareness, prevention, and treatment

3:50 -4:50

Oral presentations from submitted abstracts

4:50 -5:30

Karen Fowler: Building passive and active surveillance systems for congenital CMV
Suzanne Luck: Creating CMV-related treatment registries of pregnant women and infants

5:30 -5:45

Break

Plenary II: Postnatal Treatment

5:45 -6:30

David Kimberlin: Benefits and risks of current antiviral treatments for children with congenital CMV
John Eichwald: Hearing loss detection and intervention for children with congenital CMV
Ira Adams-Chapman: Language, educational, and other non-pharmaceutical interventions for children with congenital CMV

6:30 -7:00

Oral presentations from submitted abstracts

Reception and Poster Session

7:00 -9:00

Catered reception at CDC's Global Health Odyssey in the Tom Harkin Global Communications Center

7:30 -8:30

Poster session

November 6 - Thursday Morning

7:00 -8:00

Breakfast

Concurrent Family Session

8:00 -11:00

This section will be updated as the meeting agenda is finalized.

Concurrent Scientific Session: Pathogenesis

8:00 -8:30

Lenore Pereira: CMV pathogenesis and hypoxia at the uterine-placental interface

8:30 -10:45

Oral presentations from submitted abstracts

10:45 -11:15

Break

Plenary III: Awareness and behavioral interventions

11:15 -11:30

Sheri Bate: Behavioral intervention for congenital CMV

11:30 -12:30

Roundtable presentation and discussion on congenital CMV awareness:

Meredith Goff, Christine Prue, Jay Schulkin, Linda Smith:

What do research, theory, and practice reveal about reaching women, nurse-midwives, obstetrician/gynecologists, and child care providers with a CMV prevention message?

How can congenital CMV researchers build collaborations with these constituencies?

November 6 - Thursday Afternoon

Plenary IV: Advocacy

12:30 -2:00

Lunch and Forum on Advocacy

1:00 -2:00

Panel presentations and audience Q&A:
Godfrey Oakley: Lessons learned from folic acid and how they can be applied to congenital CMV
Jennifer L. Howse: How the March of Dimes has successfully influenced policy to improve children's health

1:00 -2:00

Poster viewing

Plenary V: Prenatal Diagnosis, Prognostic Indicators, Correlates of Immunity, and Treatment

2:00 -2:40

Maria Grazia Revello: The current state of CMV prenatal diagnosis
Stuart Adler: Findings from CMV hyperimmune globulin treatment trials

2:40 -3:55

Oral presentations from submitted abstracts

3:55 -4:10

Break

4:10 -5:20

Roundtable presentation and discussion on prenatal screening:

Catherine Donner, Tiziana Lazzarotto, Yves Ville, Benjamin Wilfond, Dana Wolf:

What are the pros and cons of screening in your country?

What would improve your screening program?

What are the ethical considerations of prenatal screening?

How do societal and political views of abortion affect prenatal screening?

5:00 -10:00

Georgia Aquarium Event: Aquarium Viewing and Gala Banquet

November 7 - Friday Morning

7:00 -8:00

Breakfast

Plenary VI: Vaccines

8:00 -8:30

Robert Pass: Update on the CMV gB vaccine

8:30 -9:30

Oral presentations from submitted abstracts

9:30 -10:15

Roundtable presentations:

Mark Schleiss: Animal models

Stanley Plotkin: Vaccine targets

Paul Griffiths: Vaccine trial endpoints

10:15 -10:35

Break

Plenary VII: Newborn screening

10:35 -11:15

Rodney Howell: U.S. newborn screening policy
Scott D. Grosse: Issues related to congenital CMV newborn screening

11:15 -11:45

Oral presentations from submitted abstracts

November 7 Friday Afternoon

11:45 -12:45

Lunch

12:45 -1:25

Roundtable presentations:

Maria Barbi, Suresh Boppana, Sheila Dollard, Naoki Inoue:

What are the benefits and challenges associated with CMV testing of dried blood spots?

Could CMV newborn screening be done with alternative specimens?

1:25 -1:45

Roundtable discussion and questions from the audience

Conclusion

1:45 -2:00

Michael Cannon: Public Health Action towards Awareness, Prevention, and Treatment-Next Steps